Ann: Response to ASX Query, page-46

Well ST, you probably wouldn't have heard about it as nothing about it was ever announced to the ASX.
From Courier Mail July 29, 2013

"Invitrogen, a multibillion-dollar US company, licensed the VitroGro stem cell media technology in 2007. Tissue Therapies chief executive Stephen Mercer told the stock market at the time that products based on it would be launched later that year and the deal's announcement prompted a 25 per cent rise in the Brisbane-based company's share price. No products were ever sold.Dr Mercer said the retraction of the QUT researchers' 2010 paper was ``commercially immaterial to the company'' and there had been no need to tell investors or the stock market.Stem cell cultivation had always been ``a side-show'' for Tissue Therapies, Dr Mercer said. The company was now focusing on wound-healing uses for VitroGro rather than stem cell cultivation, which was too small a market."

``One paper doesn't prove or disprove anything is a general principle in science, certainly clinical science,'' he said.``At this stage, on the information I have, it just doesn't seem material.``But we are a conservative company and we do look at this stuff continually.''Dr Mercer said he was unaware of the allegedly fraudulent application for federal grant money.He said Invitrogen had shelved the technology because other ingredients for the formula had proved too expensive.Invitrogen declined to comment other than to say it had moved on to other products.``Companies like Invitrogen don't spend a year of their R&D staff and sign a contract on something they don't think worked,'' Dr Mercer said."

Maybe Dr Mercer or maybe they did the research and found it didnt work?